Cargando…

Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1

Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react w...

Descripción completa

Detalles Bibliográficos
Autores principales:	NISHIBORI, Shoma, SAKURAI, Masashi, KAGAWA, Yumiko, UCHIDA, Kazuyuki, NAKAGAWA, Takayuki, IGASE, Masaya, MIZUNO, Takuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Veterinary Science 2023
Materias:	Clinical Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315546/ https://www.ncbi.nlm.nih.gov/pubmed/37150603 http://dx.doi.org/10.1292/jvms.23-0003

Ejemplares similares

Development of anti-feline PD-1 antibody and its functional analysis
por: Nishibori, Shoma, et al.
Publicado: (2023)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
por: Maekawa, Naoya, et al.
Publicado: (2023)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)

Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B) monoclonal antibodies
por: IGASE, Masaya, et al.
Publicado: (2020)

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
por: Straub, Melanie, et al.
Publicado: (2016)

Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India
por: Anthony, Michael L, et al.
Publicado: (2022)

Pathological and immunohistochemical features of 45 cases of feline meningioma
por: SAITO, Ryo, et al.
Publicado: (2021)

Immunohistochemical studies on meningoencephalitis in feline infectious peritonitis (FIP)
por: WANG, Huanan, et al.
Publicado: (2018)

The expression of platelet-derived growth factor and its receptor in canine and feline meningiomas
por: SAITO, Ryo, et al.
Publicado: (2023)

Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics
por: Alrehaili, Amani A, et al.
Publicado: (2023)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)
por: Ma, Jing, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas
por: Kelany, Mohamed, et al.
Publicado: (2021)

Histological and immunohistochemical studies on primary intracranial canine histiocytic sarcomas
por: THONGTHARB, Atigan, et al.
Publicado: (2015)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

Feline papillomavirus-associated Merkel cell carcinoma: a comparative review with human Merkel cell carcinoma
por: CHAMBERS, James K, et al.
Publicado: (2023)

Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma
por: García, Alejandro, et al.
Publicado: (2020)

A case of feline temporal lobe epilepsy with hippocampal sclerosis and dentate gyrus malformation
por: CHAMBERS, James K., et al.
Publicado: (2022)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

A Feline Case of Hepatic Neuroendocrine Carcinoma with Gastrin Immunoreactivity
por: KITA, Chiaki, et al.
Publicado: (2014)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
por: Nascimento, Catarina, et al.
Publicado: (2020)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kojima, Kensuke, et al.
Publicado: (2021)

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
por: Maekawa, Naoya, et al.
Publicado: (2016)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Immunohistochemical Analysis of PD-1 and FOXP3 in Tumor-Infiltrating Lymphocytes in Human Gliomas
por: Kanagaraj, Priyanka, et al.
Publicado: (2023)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Molecular cloning of canine Wilms’ tumor 1 for immunohistochemical analysis in canine tissues
por: SAKAI, Osamu, et al.
Publicado: (2017)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

A Retrospective Histopathological Survey on Canine and Feline Liver Diseases at the University of Tokyo between 2006 and 2012
por: HIROSE, Naoki, et al.
Publicado: (2014)

Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
por: Imai, Yushi, et al.
Publicado: (2020)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lo16lv7n54ojb07u2jjui5h090